Three reports illustrate the wide and deepening disconnect between medicine under the influence of pharmaceutical industry marketing goals and scientific evidence that contradicts current practice and public health policies:
APA "Diagnostic Statistical Manual" Task Force has been shown to have financial relationships with drug manufacturers.
Dr. Robert Spitzer, who has continued to play a central role in DSM revisions since 1980, claim he does not think a conflict of interest exists.
See list of APA Task Force on DSM-IV and DSM-IV Revised Text at: https://ahrp.stagenoises.ch/cms/content/view/145/27/
The undisclosed financial relationships between drug manufacturers and psychiatry’s leading "authorities" who determine what constitutes a “mental disorder” have been exposed.
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
Psychiatry’s professional practice paradigm has received a major blow.
Newly published results (phase II) from the CATIE schizophrenia treatment efficacy study sponsored by the National Institute of Mental Health comparing the most commonly used second generation drug treatments for schizophrenia and depression, is highly disturbing.
A report in The New Scientist, "Prescribing of Hyperactivity Drugs is Out of Control," shows just how deviant U.S. prescribing of psychostimulants for
children is compared to the rest of the world.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
The Associated Press reports that a just released study that found that a staggering, two and half million children in the U.S. are being prescribed antipsychotics annually–that’s 40 out of every 1,000 children.
The Boston Globe reports (below): “More than 50 years after psychiatrists began widely dispensing drugs to treat mental illness, the profession is coming face to face with a humbling reality: Its treatments often fail, leaving millions of patients [ ] to suffer while doctors search for something that works.”
An analysis published in the current issue of the British J of Psychiatry (BJP) of the suicide rate among schizophrenia patients treated at the same hospital in North Wales (UK) before psychotropic drugs and patients treated (in and out of hospital) with neuroleptics and /or atypical antipsychotics, found a 20-fold increase in the suicide rate since use of psychotropic drugs.
